Status:
COMPLETED
Safety and Effectiveness of D-Cycloserine in Children With Autism
Lead Sponsor:
Indiana University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
National Alliance for Research on Schizophrenia and Depression
Conditions:
Autistic Disorder
Eligibility:
All Genders
3-12 years
Phase:
PHASE3
Brief Summary
This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
Detailed Description
This project proposes to study the efficacy and safety of D-cycloserine in children with autism. The central hypothesis of this project is that D-cycloserine will be efficacious in reducing certain sy...
Eligibility Criteria
Inclusion
- Age 3 Years to 12 Years
- Diagnostic Statistical Manual Version -IV (DSM-IV) and Autism Diagnostic Interview - Revised (ADI-R)-confirmed Diagnosis of Autistic Disorder
- Aberrant Behavior Checklist (ABC) Lethargy Subscale Score of 13 or greater
Exclusion
- Children with Severe to Profound Mental Retardation
- Weight at Screening Visit \<11 kilograms
- Clinical Global Impressions-Severity Score of 7
- Presence of a Neurodevelopmental Disorder with Possible Associations to Autism: Subjects with Fragile X Syndrome, Tuberous Sclerosis, or other neurodevelopmental disorders known to be associated with autism or autistic features will be excluded.
- Presence of a Psychiatric Disorder that would Require a Specific Type of Treatment: Subjects with major depressive disorder, bipolar disorder, or a psychotic disorder will be excluded because treatment for these disorders often requires specific psychotropic agents. Subjects with an active substance use disorder will be excluded because of safety concerns and problems this would cause in assessing efficacy.
- Presence of a Medical Condition that would make Treatment with D-Cycloserine Less Safe: Subjects with significant cardiac, hepatic, or renal disease will be excluded due to concerns about pharmacokinetic alterations or adverse effects. Subjects with epilepsy or a history of seizures will be excluded due to rare reports of seizures with high doses of D-cycloserine. D-cycloserine is an U.S. FDA Pregnancy Category C drug. Because of the unknown effects of D-cycloserine on the developing human fetus, females of childbearing potential will be given a urine pregnancy test and required to use a suitable form of birth control during the study.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00198120
Start Date
February 1 2004
End Date
August 1 2010
Last Update
April 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
Indianapolis, Indiana, United States, 46202